An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

October 31, 2010

Conditions
Familial Amyloid PolyneuropathyATTR-PN
Interventions
DRUG

Fx-1006A

Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.

Trial Locations (11)

Unknown

FLENI Departamento de Hepatología y Transplante de Organos, Buenos Aires

Hospital Universitario Clementino Fraga Filho, Rio de Janeiro

Service de Neurologie, CHU Henri Mondor, Paris

Universitatsklinikum Munster, Transplant Hepatology, Münster

Servicio de Neurologica Piso 7, Hospital de Santa Maria, Lisbon

Unidade Clinica de Paramiloidose, Hospital Geral de Santo Antonio, Largo Prof Abdel Salazar, Porto

FAP-Teamet Familjar Amyloids, Norrlands universitetssjukhus, Umeå

C1428AQK

FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires

1649-035

Serviço de Neurologia-Hospital de Santa Maria, Lisbon

4099-001

Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto

SE-901 85

Umea University Hospital, Umeå

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY